NVS: Novartis AG Stocks News on January 11, 2025

AI, vaccine distrust, & the future of healthcare: Novartis CEO

NVS

Yahoo Finance Video

17 hours ago

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Light Horse emerges with $62m and Novartis partnership worth up to $1bn

NVS

Pharmaceutical Technology

18 hours ago

Light Horse emerges with $62m and Novartis partnership worth up to $1bn

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

2 days ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Why Novartis (NVS) is a Top Value Stock for the Long-Term

NVS

Zacks

4 days ago

Why Novartis (NVS) is a Top Value Stock for the Long-Term

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

NVS

Zacks

4 days ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

NVS

Zacks

8 days ago

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

Positive data could expand use of Novartis’ gene therapy for SMA

NVS

Clinical Trials Arena

8 days ago

Positive data could expand use of Novartis’ gene therapy for SMA

Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals

NVS

BioPharma Dive

9 days ago

Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals

Novartis' Gene Therapy Meets Primary Endpoint in SMA Study

NVS

Zacks

10 days ago

Novartis' Gene Therapy Meets Primary Endpoint in SMA Study

Here's Why Novartis (NVS) is a Strong Growth Stock

NVS

Zacks

11 days ago

Here's Why Novartis (NVS) is a Strong Growth Stock

Novartis’ Gene Therapy Shows Promise in Treating SMA

NVS

TipRanks

11 days ago

Novartis’ Gene Therapy Shows Promise in Treating SMA

Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint

NVS

Clinical Trials Arena

11 days ago

Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint

NVS

MT Newswires

12 days ago

Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

NVS

GlobeNewswire

12 days ago

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

NVS

Insider Monkey

13 days ago

Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

NVS

MT Newswires

14 days ago

Sector Update: Health Care Stocks Lower in Late Afternoon Trading

NVS

MT Newswires

14 days ago

Sector Update: Health Care

NVS

MT Newswires

15 days ago

Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, US Appeals Court Rules

Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules

NVS

Reuters

15 days ago

Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules

Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?

NVS

Insider Monkey

18 days ago

Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?

Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term

NVS

Zacks

19 days ago

Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

22 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

NVS

MT Newswires

23 days ago

Update: Novartis to Close MorphoSys Sites, Affecting 330 Jobs

NVS

MT Newswires

23 days ago

Market Chatter: Novartis to Close MorphoSys Sites, Affecting 330 Jobs

Novartis shutters MorphoSys sites, lays off staff

NVS

BioPharma Dive

23 days ago

Novartis shutters MorphoSys sites, lays off staff

BioAge and Novartis seek drug targets for ageing-related diseases

NVS

Pharmaceutical Technology

23 days ago

BioAge and Novartis seek drug targets for ageing-related diseases

Novartis says 330 jobs hit as it closes MorphoSys sites

NVS

Reuters

23 days ago

Novartis says 330 jobs hit as it closes MorphoSys sites

NVS

MT Newswires

24 days ago

BioAge Labs Says it is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

NVS

Zacks

24 days ago

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now

NVS

Insider Monkey

24 days ago

Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now

NVS vs. LLY: Which Stock Should Value Investors Buy Now?

NVS

Zacks

25 days ago

NVS vs. LLY: Which Stock Should Value Investors Buy Now?

Are Investors Undervaluing Novartis (NVS) Right Now?

NVS

Zacks

25 days ago

Are Investors Undervaluing Novartis (NVS) Right Now?

NVS

Zacks

a month ago

The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology

Top Stock Reports for Mastercard, Procter & Gamble & Novartis

NVS

Zacks

a month ago

Top Stock Reports for Mastercard, Procter & Gamble & Novartis

NVS

MT Newswires

a month ago

Monte Rosa Closes Global License Agreement With Novartis

NVS

MT Newswires

a month ago

Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

NVS

GlobeNewswire

a month ago

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

Novartis Announces Positive Results From Late-Stage Study on Fabhalta

NVS

Zacks

a month ago

Novartis Announces Positive Results From Late-Stage Study on Fabhalta

Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta

NVS

Clinical Trials Arena

a month ago

Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta

NVS

GlobeNewswire

a month ago

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

NVS

MT Newswires

a month ago

Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

NVS

GlobeNewswire

a month ago

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

Why Novartis (NVS) is a Top Growth Stock for the Long-Term

NVS

Zacks

a month ago

Why Novartis (NVS) is a Top Growth Stock for the Long-Term

PTC Therapeutics price target raised to $71 from $47 at UBS

NVS

TipRanks

a month ago

PTC Therapeutics price target raised to $71 from $47 at UBS

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

NVS

Zacks

a month ago

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

NVS

Zacks

a month ago

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

NVS

Zacks

a month ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Novartis and Olema expand alliance with $250m to boost breast cancer trials

NVS

Pharmaceutical Technology

a month ago

Novartis and Olema expand alliance with $250m to boost breast cancer trials

Novartis and PTC Therapeutics link to develop Huntington’s therapy

NVS

Pharmaceutical Technology

a month ago

Novartis and PTC Therapeutics link to develop Huntington’s therapy

NVS

MT Newswires

a month ago

Sector Update: Health Care Stocks Slipping Late Afternoon

NVS

MT Newswires

a month ago

Sector Update: Health Care Stocks Softer Monday Afternoon

NVS

MT Newswires

a month ago

Sector Update: Health Care

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

NVS

Benzinga

a month ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

NVS

Investopedia

a month ago

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

NVS

GuruFocus.com

a month ago

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate

NVS

MT Newswires

a month ago

PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone

NVS

Investor's Business Daily

a month ago

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone

NVS

MT Newswires

a month ago

Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement

NVS

MT Newswires

a month ago

PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

NVS

PR Newswire

a month ago

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

NVS

Zacks

a month ago

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

2 Dividend Stocks to Buy and Hold Forever

NVS

Motley Fool

a month ago

2 Dividend Stocks to Buy and Hold Forever

NVS

Insider Monkey

a month ago

Novartis AG (NVS): A Bull Case Theory

Why Novartis AG (NVS) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

NVS

Insider Monkey

a month ago

Why Novartis AG (NVS) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

NVS

Zacks

a month ago

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer

NVS

Zacks

a month ago

EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer

EC approves Novartis’ Kisqali to treat early breast cancer

NVS

Pharmaceutical Technology

a month ago

EC approves Novartis’ Kisqali to treat early breast cancer

NVS

MT Newswires

a month ago

Novartis Receives European Commission Approval for Adjuvant Early Breast Cancer Treatment

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

NVS

GlobeNewswire

a month ago

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

NVS

Zacks

2 months ago

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

Novartis to present data from mpre than 65 abstracts as ASH, SABCS

NVS

TipRanks

2 months ago

Novartis to present data from mpre than 65 abstracts as ASH, SABCS

NVS

Zacks Small Cap Research

2 months ago

MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

NVS

GlobeNewswire

2 months ago

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Are Hedge Funds Banking on Novartis AG (NVS)’s Core Income Growth?

NVS

Insider Monkey

2 months ago

Are Hedge Funds Banking on Novartis AG (NVS)’s Core Income Growth?

Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

NVS

Zacks

2 months ago

Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

NVS

Zacks

2 months ago

Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

Novartis provides updates to mid-term guidance, now sees 6% sales CAGR 2023-2028

NVS

TipRanks

2 months ago

Novartis provides updates to mid-term guidance, now sees 6% sales CAGR 2023-2028

Novartis acquires Kate Therapeutics to advance gene therapies

NVS

Pharmaceutical Technology

2 months ago

Novartis acquires Kate Therapeutics to advance gene therapies

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

NVS

Benzinga

2 months ago

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

NVS

MT Newswires

2 months ago

Novartis Upgrades Mid-Term Sales Growth Guidance

Novartis Lifts Midterm Sales Guidance Amid U.S. Expansion

NVS

The Wall Street Journal

2 months ago

Novartis Lifts Midterm Sales Guidance Amid U.S. Expansion

Novartis wagers more than $1B on gene therapies for the nervous system

NVS

BioPharma Dive

2 months ago

Novartis wagers more than $1B on gene therapies for the nervous system

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

NVS

GlobeNewswire

2 months ago

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Novartis ranks first in 2024 Access to Medicine Index

NVS

GlobeNewswire

2 months ago

Novartis ranks first in 2024 Access to Medicine Index

Novartis strengthens radiopharma leadership with Ratio Therapeutics deal

NVS

Pharmaceutical Technology

2 months ago

Novartis strengthens radiopharma leadership with Ratio Therapeutics deal

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

NVS

BioPharma Dive

2 months ago

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

2 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

NVS

MT Newswires

2 months ago

Novartis Pharma, Ratio Therapeutics Collaborate to Develop Cancer Treatment Candidate

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

NVS

PR Newswire

2 months ago

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

NVS

Morningstar Research

2 months ago

Analyst Report: Novartis AG

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

NVS

Pharmaceutical Technology

2 months ago

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

NVS

MT Newswires

2 months ago

Novartis Says Talks for Prostate Cancer Treatment Close Without Deal

Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus

NVS

Zacks

2 months ago

Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Here's Why Novartis (NVS) is a Strong Value Stock

NVS

Zacks

2 months ago

Here's Why Novartis (NVS) is a Strong Value Stock

Ouch: Why a Healthcare Selloff Really Hurts in Europe

NVS

The Wall Street Journal

2 months ago

Ouch: Why a Healthcare Selloff Really Hurts in Europe

Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

NVS

Zacks

2 months ago

Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

NVS

Zacks

2 months ago

Zacks.com featured highlights include Janus Henderson, Coastal Financial, Novartis, Apogee and InterDigital

Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

NVS

Zacks

2 months ago

Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

NVS

Zacks

2 months ago

Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

5 Low-Leverage Stocks to Buy Amid the Focus on Inflation Data

NVS

Zacks

2 months ago

Latest Novartis AG (NVS) News on January 11, 2025

Share on Social Networks: